The Medicines Company: Innovating Innovation

The Medicines Company expects its cardiovascular outcomes trial for Inclisiran can be completed at one-tenth the cost of rival drug trials, without cutting corners

Read the full post on Forbes - Healthcare

Anne Marie Knott, Contributor